Astellas Enters Into License Agreement With TOLMAR

Expansion of Territory for Eligard(R) in Asia, Middle East, Africa and CIS

TOKYO, January 17, 2011 - Astellas Pharma Inc. (TSE:4503"Astellas") announced today that its
European subsidiary Astellas Pharma Europe Ltd.("Astellas Pharma Europe",
headquarters: Stains, U.K.)" acquired the license for commercialization of
the treatment for advanced prostate cancer Eligard(R) from TOLMAR Inc.
("TOLMAR", headquarters: Colorado, U.S.A.) on December 22, 2010 in a
selection of Asian, Middle Eastern, North African and Commonwealth of
Independent States (CIS) countries.

Eligard is a luteinizing hormone-releasing hormone (LHRH) agonist which
Astellas Pharma Europe in-licensed from TOLMAR and Astellas Pharma Europe
registered and launched Eligard successfully in the vast majority of European
countries. Under the terms of the new agreement, the commercialization of
Eligard will be expanded to the Middle East, North Africa, CIS, Central Asia
and Asian markets such as China, Taiwan, Thailand, Hong Kong, the Philippines
and Indonesia.

Astellas puts a high strategic focus on the therapeutic area of urology,
by commercializing a treatment for overactive bladder, Vesicare(R), and a
treatment for functional symptoms of benign prostatic hyperplasia, Omnic(R),
Omnic Ocas(R) (sold under the names Harnal(R) in Japan) This new agreement
could reinforce the presence of the therapeutic area, as well as a bridgehead
for the entry into the therapeutic area of oncology, Astellas' third
prioritized area alongside urology and transplant in emerging markets
including Asia.

About Astellas

Astellas Pharma Inc., located in Tokyo, Japan, is a pharmaceutical
company dedicated to improving the health of people around the world through
the provision of innovative and reliable pharmaceutical products. Astellas
has approximately 16,000 employees worldwide. The organization is committed
to becoming a global category leader in urology, immunology & infectious
diseases, neuroscience, DM complications & metabolic diseases and oncology.
For more information on Astellas Pharma Inc., please visit our website at
www.astellas.com/en.

Contacts for inquiries or additional information: Astellas Pharma Inc., Corporate Communications, Tel: +81-3-3244-3201 Fax: +81-3-5201-7473